Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

The OReO study will investigate the efficacy and safety of Olaparib maintenance re-treatment in patients with relapsed non-mucinous EOC, who have had disease progression following maintenance therapy with a Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerisation inhibitor (PARPi) and a complete or partial radiological response to subsequent treatment with platinum-based chemotherapy …

Phase

0.0 miles

Learn More »

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

Regarding the mechanisms of unexplained RM, on the basis of animal models and clinical studies, many hypotheses were raised: Reduced ovarian reserve, Progesterone defect: a double-blind trial did not show any benefit of progesterone therapy. Thrombotic mechanisms and/or endothelial dysfunction: An association with some inherited thrombophilias was suggested. A prothrombotic …

Phase

0.0 miles

Learn More »

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

The primary objective of this study is to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or standard care alone (PDS or IDS alone). Secondary objectives of the study include: Evaluating the efficacy of HIPEC in terms …

Phase

0.0 miles

Learn More »

A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the …

Phase

0.0 miles

Learn More »

Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies

A pregnancy is considered ''prolonged'' from 41 weeks of gestation. Prolonged Pregnancies (PP) are associated with increased maternal morbidity: emergency caesarean, 3rd and 4th degree perineal lesions and postpartum haemorrhage. Foetuses are at increased risk of oligohydramnios, meconium-staining and Fetal Heart Rate (FHR) anomalies. Around 15% of all pregnancies are …

Phase

0.0 miles

Learn More »

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

The patient received before the surgery a second line chemotherapy, platinum-based regimen with either carboplatine-paclitaxel, or carboplatine-caelyx. At the end of the six courses IV chemotherapy, if the disease is still responding and if a complete cytoreductive surgery seems possible, the patient is included after signed informed consent and will …

Phase

1.37 miles

Learn More »

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.

Routine exams required for diagnosis: Endometrioid biopsy or product of a dilatation-curettage under hysteroscopy for diagnosis of histologic typing Tumor assessment: Lombopelvic MRI (1.5 or 3T) with gadolinium injection, studied by steady and dynamic sequences. US and CT-Scan in case of intolerance to MRI should be discussed. FDG-PET may be …

Phase

1.37 miles

Learn More »

MEdical Versus SUrgical Treatments of Rectal Endometriosis

The purpose of this study is to determine whether, in women with deep endometriosis involving the rectum and not intending to get pregnant, continuous hormonal treatment would be followed by better digestive functional outcomes than curative rectal surgery. Are included women from 35 to 50 years presenting with deep endometriosis …

Phase

1.63 miles

Learn More »

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the management of moderate to severe EAP …

Phase

1.63 miles

Learn More »